Lazertinib: on the Way to Its Throne

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are crucial in treating non-small cell lung cancer (NSCLC).
• Acquired resistance mutations, such as T790M, limit the efficacy of earlier generation EGFR TKIs.
• Lazertinib represents a third-generation EGFR TKI designed to overcome resistance mechanisms.

Purpose of the Study:

• To review the preclinical and clinical data of lazertinib.
• To discuss the therapeutic potential of lazertinib in EGFR-mutant NSCLC.
• To explore future perspectives for lazertinib in NSCLC treatment.

Main Methods:

• Systematic review of preclinical studies evaluating lazertinib's mechanism of action and selectivity.
• Analysis of clinical trial data (e.g., LASER201) assessing lazertinib's efficacy and safety in NSCLC patients.
• Comparison of lazertinib's profile with existing EGFR TKIs like osimertinib.

Main Results:

• Lazertinib is an oral, irreversible EGFR TKI with high selectivity for sensitizing and T790M mutations.
• Phase I/II trial (LASER201) demonstrated encouraging anti-tumor activity in advanced/metastatic NSCLC patients with EGFR T790M mutations.
• Lazertinib exhibits a favorable safety profile with a potentially lower risk of skin and cardiac adverse events compared to osimertinib.

Conclusions:

• Lazertinib is approved for EGFR T790M-mutated NSCLC patients previously treated with EGFR TKIs.
• Ongoing investigations explore lazertinib as a first-line monotherapy and in combination with amivantamab.
• Lazertinib holds significant promise for improving outcomes in EGFR-mutant NSCLC.